CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
November 21, 2017 08:00 ET
|
Crown Bioscience
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial
January 24, 2017 09:10 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments....
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
October 15, 2015 09:25 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - October 15, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli...
Celgene May Also Want to Take Notice of PharmaCyte Biotech
July 24, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 24, 2015) - A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a...
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
July 21, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 21, 2015) - In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is,...
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
July 13, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 13, 2015) - While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
March 18, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
October 14, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
June 04, 2014 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
April 17, 2014 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...